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T R A N S F U S I O N  P R A C T I C E
 
Delayed platelet engraftment in group O patients after autologous 
progenitor cell transplantation
 




 Fucosylated glycans, including H-
antigen, play critical roles in hematopoietic progenitor cell 
homing, adhesion, growth, and differentiation. H-active 





cells and committed megakaryocytic progenitors and may 
mediate adhesion to marrow stromal fibroblasts. We 
examined the possible influence of donor ABO type on 
platelet (PLT) engraftment after autologous peripheral 
blood progenitor cell transplant (PBPCT).
 
STUDY DESIGN AND METHODS:
 
 A retrospective 
analysis of all patients who underwent a single 
autologous PBPCT between 1996 and 2000 were 
reviewed. Neutrophil and PLT engraftment were 




 cell dose by 
t test, chi-square test, analysis of variance, Kaplan-Meier 




 Engraftment data was available in 195 
patients. PLT engraftment was delayed in all patients, 

























 0.001). When examined by ABO 













significantly delayed in group O patients relative to 





 0.001). Approximately 50 percent of group O patients 









 A group O phenotype may be 
associated with delayed PLT engraftment at lower CD34 
doses.
 
ell-surface carbohydrates, particularly those
containing fucose, play integral roles in hemato-














Table 1) are two blood group–related antigens that serve
as ligands for selectins (L-, P-, and E-selectin)—a family of



















early lymphoid progenitors, monocytes, and granulo-
cytes, where they facilitate homing to marrow sinusoids,





also plays a central role in the Notch signaling pathway,
an evolutionarily conserved system regulating cell differ-





 favoring lymphoid and dendritic cell





 Loss and/or modification of
several unusual O-linked fucoses present on epidermal
growth factor repeats can profoundly alter Notch ligand




There is increasing evidence that H- and H-active
antigens may also be developmentally important antigens








 progenitor cells are positive for
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, and FUT1 is relatively spe-
cific for early hematopoietic progenitors and is lost with




H-antigen may also play a role in megakaryocytic dif-
ferentiation. H-antigen is commonly expressed in mega-
karyoblastic leukemia, in conjunction with CD34 and





 Likewise, monoclonal antibody MG-2 (MoAb
MG-2), an antibody against early megakaryocytic pro-
genitors and megakaryoblastic leukemia, appears to re-





megakaryoblastic cell lines, H- and MG-2 antigens are
progressively lost with increasing megakaryocytic matura-









 have reported that megakaryocyte adhesion
to marrow stromal fibroblasts is fucose-dependent, inhib-





soluble H-antigen. A role for H-antigen in mediating stro-
mal cell adhesion could have important implications for
ex vivo megakaryocyte expansion as well as platelet (PLT)
recovery following chemotherapy and marrow transplan-
tation. Expansion and long-term preservation of mega-
karyocytic progenitors requires direct contact and





Based on these findings, we hypothesized that ABO
type may influence the rate of PLT engraftment after che-
motherapy or autologous progenitor cell transplant. Spe-
cifically, we hypothesized that group O patients may have
accelerated PLT recovery owing to prolonged expression
of H-antigen on developing megakaryocytes. To examine
this question, we retrospectively reviewed WBC and PLT
engraftment times in patients undergoing an autologous






The study was confined to a retrospective analysis of all
patients who underwent autologous peripheral blood
progenitor cell (PBPC) collection at our institution
between 1996 and 2000. Inclusion criteria were an age of
more than 18 years at the time of PBPC collection, fol-
lowed by a single autologous PBPCT at our institution. Of
263 patients who underwent PBPC collection, 195 (74%)
were included for analysis (Table 2). Sixty-eight patients
were excluded because of a prior transplant or back-to-




 16), transplant with PBPCs



























patients were enrolled in clinical trials approved by the
human research institutional review board of the Univer-
sity of Michigan. Informed consent was obtained from all
patients before leukapheresis and treatment.
 
TABLE 1. Fucosylated glycans in hematopoiesis
 



























































                              
















































                






















































                                   





















































































































































ABO AND PLT ENGRAFTMENT IN PBPCT
 




PBPC mobilization and collection
 
PBPCs were mobilized in all patients by a combination of
disease-oriented chemotherapy and granulocyte–colony-




g per kg per day). Six





day) owing to poor PBPC mobilization and collection. One
patient failed to collect and was remobilized with a com-
bination of granulocyte-macrophage–colony-stimulating









PBPC collection was initiated when the peripheral WBC








 per L after chemotherapy.
PBPCs were collected by processing two blood volumes by
standard continuous-flow leukapheresis on an apheresis
machine (COBE Spectra, COBE BCT Inc., Lakewood, CO).
Leukocytopheresis was performed daily until a minimum








 CD34+ cells per kg of body weight
were collected. Cells were volume-adjusted to a final con-








 WBCs per mL in 10 percent









C/min to -90∞C), and stored in the liquid phase of
liquid nitrogen.
Product analysis
An aliquot of each leukocytopheresis collection was sub-
jected to a complete blood count with WBC differential.
Hematopoietic colony assays were not routinely per-
formed per our institution’s transplant program guide-
lines. CD34+ yields and cell viability
were determined by a whole-blood lysis
technique and flow cytometry as rec-
ommended by the International Society
of  Hematology  and  Graft  Engineer-
ing (ISHAGE).19 Samples (30 mL) were
stained with a phycoerythrin-labeled
monoclonal anti-CD34 (MoAb 581), flu-
orescein-labeled anti-CD14 (MoAb MY-
4), energy-coupled dye–labeled CD45
(MoAb J.33), and 7-aminoactinomycin-
D (Molecular Probes, Eugene, OR) for
10 minutes at room temperature. Anal-
ysis was subsequently performed on a
flow cytometer (Coulter EPICS XL-MCL,
Beckman Coulter, Miami, FL) with
ISHAGE acquisition layouts. Briefly,
mononuclear cells (MNCs) were initially
gated on CD45 fluorescence, side and
forward scatter. Nonviable cells were
excluded based on 7-aminoactinomy-
cin-D fluorescence. The percentage of
CD34+ cells was determined in the
CD45+, CD14– fraction after counting
50,000 events. To calculate the total
CD34+ cell yield, the percentage of
CD34+ cells was multiplied by the total number of MNCs
collected. All MoAbs used were purchased from Immuno-
tech (Miami, FL).
Definitions of engraftment and CD34+ cell dose
Times for WBC and PLT engraftment were calculated from
the day of PBPC infusion (Day 0). Neutrophil or WBC
engraftment was defined as the first of three consecutive
days to achieve a sustained absolute neutrophil count of
at least 0.5 ¥ 109 WBCs per L. Early PLT engraftment was
defined as the first day to achieve a sustained PLT count
of greater than 20 ¥ 109 per L (20 ¥ 109/L) in the absence of
PLT transfusion support for at least 72 hours. Late PLT
engraftment was defined as the first day to achieve a sus-
tained, independent PLT count of greater than 50 ¥ 109 per
L in the absence of transfusion support.20,21
Because engraftment times are dependent on the
number of CD34+ cells infused,20-22 we also classified
patients as receiving a high, intermediate, and low PBPCT
dose, based on the total number of CD34+ PBPCs infused
at transplant. High dose was considered a weight-adjusted
CD34 dose of at least 5 ¥ 106 CD34+ cells per kg body
weight. Previous studies have reported that 5 ¥ 106 CD34
per kg of body weight is the threshold dose predictive for
rapid PLT engraftment.20-24 Intermediate and low doses
were arbitrarily established at a CD34+ cell dose of 3 ¥ 106
to 5 ¥ 106 CD34+ cells per kg of body weight and 2 ¥ 106 to
3 ¥ 106 CD34+ cells per kg of body weight, respectively. All
TABLE 2. Patient characteristics
Characteristic Number Percentage
All patients 195 100
Diagnosis
Hodgkin’s lymphoma 53 27.2
Non-Hodgkin’s lymphoma 64 32.8
Multiple myeloma 63 32.3
Breast cancer 13 6.7
Ewing’s sarcoma 1 0.5








Group A 85 43.6
Group O 74 38.5
Group B 24 12.3
Group AB 12 6.0
CD34 cell dose (¥106/kg of body weight)
Low (2 to <3) 76 39
Intermediate (3 to 5) 40 20.5




Early (>20 ¥ 109/L) 170 87
Late (>50 ¥ 109/L) 155 79.5
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patients analyzed received at least 2 ¥ 106 CD34+ cells per
kg of body weight in accordance with our institution’s
guidelines.
Transfusion support
Patients were transfused with irradiated, leukoreduced
red blood cells (RBCs) and whole blood–derived pooled
PLT concentrates (5 units/dose) to maintain a minimum
hemoglobin level of 8.0 g per dL and a PLT count of
greater than 10 ¥ 109 per dL according to clinical guide-
lines and underlying medical condition. Patients were
rarely transfused with single-donor apheresis PLTs (<1%
total). Transfusion support was determined by the total
number of RBCs and whole blood–derived PLT equiva-
lents transfused during their admission for PBPCT. Single-
donor apheresis PLTs, when given, were considered
equivalent to seven whole blood–derived PLT
concentrates.
Records were also reviewed in 54 patients trans-
planted at low CD34 doses for evidence of PLT refractori-
ness, based on an initial request for either single-donor
apheresis PLTs or cross-matched or HLA-matched PLTs.
No patient reviewed had a request for special PLT prod-
ucts. Two patients received a single unit of apheresis PLTs
based on available inventory.
Statistical analysis
WBC and PLT engraftment times were
analyzed and compared relative to
CD34+ cell dose and patient ABO type
and expressed as the mean ± standard
deviation except as indicated. Mean
engraftment  rates  were  compared  by
a two-tailed t test. The probability of
early and late PLT engraftment were
calculated with the method of Kaplan
and Meier25 and compared by the log-
rank test. In patients transplanted at
low CD34+ cell doses, categorical vari-
ables were assessed by a chi-square
test, a t test, and a multivariate analy-
sis of variance. A result was considered
significant at a p value of less than
0.05. Because of a limited number of
group AB and B patients, statistical
comparisons were typically limited to
group O, group A, and all non-group O
patients (groups A, B, and AB). Graph-
ics and statistical analysis were per-
formed with computer software
(Kaleidograph, Synergy Software,




A total of 195 patients, who underwent a single autologous
PBPCT, were available for analysis (Table 2). More than
90 percent of patients received transplants for an under-
lying hematologic malignancy. Overall, there was a slight
predominance in men and the group A phenotype in our
study cohort. There was a broad range in the number of
CD34+ PBPCs collected and infused (Table 2; Fig. 1). A
comparison of patients in the three CD34+ dose categories
found no significant differences by sex, ABO type, or
underlying diagnosis (data not shown).
Of our 195 patients, WBC engraftment data were
available in 100 percent of patients. Although all patients
had achieved WBC engraftment at the time of discharge,
data regarding PLT engraftment were only available in
87 percent of patients; the remaining 13 percent (n = 25)
were still PLT transfusion–dependent at discharge.
Because these latter patients were followed by their local
physicians after discharge, it was not possible to docu-
ment when early and late PLT engraftment occurred.
Despite the latter, full PLT engraftment was documented
at 100 days after transplant in most of these patients,
with 17 of 25 (68%) patients having PLT counts of greater
than 100 ¥ 109 per L. Poor engraftment (PLT count
<50 ¥ 109/L) and relapse (n = 3) were noted in 6 of 25
patients.
Fig. 1. Correlation between CD34+ PBPC dose and engraftment times for WBC (A) and 
early (B, >20 ¥ 109 L) and late PLT engraftment (C, >50 ¥ 109/L). A correlation between 
the time to early and late PLT engraftment was also observed (D).
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WBC engraftment
Most patients achieved an absolute neutrophil count of
greater than 0.5 ¥ 109 per L within 10 to 11 days after infu-
sion (mean ± SD, 10.8 ± 1.2; range, 7-15; n = 195), which is
comparable to other studies.20-23 There was a mean 1- to
2-day lag in WBC engraftment at lower CD34+ cell doses,
but this difference did not reach clinical significance
(Table 3; Fig. 2). There was an exponential relationship
between CD34+ cell dose and WBC engraftment (r = 0.73;
Fig. 1A). A comparison of WBC engraftment by ABO type
found no significant differences.
PLT engraftment
The mean times necessary for early and late PLT engraft-
ment were 12.7 ± 4.3 and 17.3 ± 7.7 days, respectively. As
reported, both early and late PLT engraftment were
strongly influenced by the CD34+ cell dose.20-22 On aver-
age, transplant at low CD34+ cell doses resulted in a 4- to
9-day delay in early and late PLT recovery, respectively
(Table 3; Fig. 1). There was no correlation between the
time to WBC engraftment and either early (r = 0.36) or late
PLT engraftment (r = 0.38). A positive correlation was
observed between the time to early and late PLT recovery
(r = 0.70; Fig. 1D), particularly at low CD34+ doses
(r = 0.80; data not shown).
As noted by others,20-24 a CD34+ dose of greater than
5 ¥ 106 per kg of body weight was highly predictive of rapid
PLT recovery (Fig. 2). Early PLT engraftment was observed
in these patients by Day 20 in 97 percent of patients, with
the majority of patients engrafting between Day 10 (44%)
and Day 12 (83%). Late PLT recovery was observed by
Days 15 (76%) and 20 (92%). Rapid PLT recovery was also
observed in most patients transplanted at a CD34+ cell
dose of greater than 3 ¥ 106 per kg. At these intermediate
CD34+ cell doses, early and late PLT recovery was
observed by Day 12 (74% of patients) and Day 20 (82%),
respectively. In contrast, only 22 percent of patients trans-
planted at a CD34+ cell dose of less than 3 ¥ 106 per kg of
body weight achieved a PLT count of greater than 20 ¥ 109
per L by Day 12. Although they were excluded from our
analysis, it is noteworthy that five of six patients with
either poor PLT engraftment or relapse at Day +100 after
transplant were transplanted at low CD34+ cell doses
(2.4 ± 0.4; range, 2.1-3.0).
The effect of ABO on PLT engraftment
To examine whether ABO group can influence PLT
engraftment, we specifically examined PLT engraftment
times by patient ABO type at all three CD34+ cell doses
(Table 3; Fig. 2). There were no significant differences in
either mean engraftment times (Table 3) or the probability
of PLT engraftment (not shown), by ABO type at transplant
doses of greater than 3 ¥ 106 per kg. At low CD34+ doses,
however, there was a trend toward delayed engraftment in
group O patients. Relative to group A and B patients, early
PLT engraftment was delayed nearly 2 days, and late
engraftment, 12 to 14 days (p < 0.001). Likewise, the prob-
ability of achieving late PLT engraftment was significantly






Engraftment in days* <3 vs. >5† vs. >3||
P value§Low (<3) Intermediate High (>5) D†§ P value†§
WBC engraftment
All patients 195 11.6 ± 1.0 10.9 ± 0.7 9.9 ± 0.9 1.7 NS NS
Non-group O 121 11.5 ± 0.9 10.9 ± 0.8 9.9 ± 1.0 1.6 NS NS
Group A 85 11.5 ± 1.0 10.9 ± 0.7 9.8 ± 0.9 1.7 NS NS
Group B 24 11.5 ± 0.8 10.7 ± 0.6 9.7 ± 1.4 1.8 NS NS
Group O 74 11.9 ± 1.1 11.0 ± 0.7 10.1 ± 0.7 1.8 NS NS
PLT engraftment (early, >20 ¥ 109/L)
All patients 132 15.2 ± 4.6 11.8 ± 1.3 10.9 ± 2.4 4.3 <0.01 <0.001
Non-group O 87 14.6 ± 4.2 11.9 ± 1.3 10.8 ± 2.1 3.8 <0.01 <0.02
Group A 67 14.5 ± 4.3 11.8 ± 1.5 10.6 ± 1.5 3.9 <0.01 <0.02
Group B 16 14.3 ± 2.5 12.5 ± 0.5 11.0 ± 4.4 3.3 <0.01 NS
Group O 45 16.0 ± 2.6 11.6 ± 1.1 11.2 ± 3.0 4.8 <0.01 <0.005
PLT engraftment (late, >50 ¥ 109/L)
All patients 103  23 ± 10.5 16.9 ± 5.6 14.1 ± 3.8 8.9 <0.001 <0.003
Non-group O 66 19.6 ± 7.9 17.1 ± 6.4 13.7 ± 3.5 5.9 <0.001 <0.02
Group A 48 18.5 ± 6.4 16.1 ± 6.5 13.7 ± 3.4 4.8 <0.001 <0.02
Group B 9 20.5 ± 2.2 13.8 ± 4.0 6.7 <0.001 NS
Group O 37 32.4 ± 13.3 16.8 ± 4.8 14.7 ± 4.2 17.7 <0.001 <0.01
* Mean ± SD.
† Comparison between CD34 dose <3 ¥ 106 per kg (low dose) and >5 ¥ 106 per kg (high dose only).
‡ Difference in days.
§ T test; NS = not significant (p > 0.05).
|| Comparison between CD34 dose <3 ¥ 106/kg and >3 ¥ 106/kg (intermediate and high dose).
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lower among group O patients at low CD34+ doses
(Fig. 3B; p < 0.001).
Analysis of patients transplanted at low CD34+ 
doses
In an effort to identify any confounding factors or vari-
ables that could account for delayed PLT recovery, we per-
formed a detailed comparison of product and patient
characteristics for all patients transplanted at low CD34+
cell doses (Table 4). Of 54 patients reviewed, 30 percent
were group O and 52 percent were group A. Overall, there
were no significant differences in patient age, sex, primary
diagnosis, number of PBPC collections required,22 CD34+
cell dose, or final MNC yield26 infused by ABO type. To
further exclude CD34+ yield as the etiology for delayed
engraftment among group O patients,
we directly compared CD34+ dose and
PLT engraftment for all patients trans-
planted at low CD34+ doses. There was
no correlation between CD34+ yield
and early (r = 0.18) and late (r = 0.10)
PLT engraftment.
A detailed comparison of late PLT
engraftment highlighted the differ-
ences between group O and non-
group O patients. Whereas 75 percent
of non-group O patients achieved a
PLT count of greater than 50 ¥ 109 per
L by Day 20, only 13 percent of
group O patients did. In fact,
50 percent of group O patients
required more than 40 days for late
engraftment. Despite this marked
delay, there were no significant differ-
ences in either PLT or RBC transfusion
support by ABO type (Table 4). This
was not surprising given the lack of
correlation between PLT recovery and
PLT (r = 0.14) and RBC utilization
(r = 0.39) in individual patients (data
not shown).27
After analysis of the data, it was
clear that delayed recovery occurred
in a subset of group O patients. We
therefore performed a subanalysis of
all patients transplanted at low CD34+
cell doses, regardless of ABO type, who
required more than 35 days for to
achieve a PLT count of greater than
50 ¥ 109 per L. As before, there were no
significant differences in sex (57%
male), age (51 ± 13 years; range, 22-
60 years), underlying diagnosis, WBC
engraftment (11.3 ± 0.5), CD34+ cell
dose (2.27 ± 0.28), and MNC dose (6.5 ± 2.2; range, 4-9.9).
Late PLT engraftment was preceded by delays in early PLT
engraftment (20.2 days; range, 15-40 days) and was
accompanied by increased PLT (40.8 ± 17.4; range, 20-70)
and RBC (6.8 ± 2.7; range, 4-11) utilization. Increased PLT
utilization was not due to PLT refractoriness: No patient
transplanted at low CD34 doses had evidence of clinical
refractoriness. Among patients requiring more than 35
days to reach late PLT engraftment, 70 percent were
group O (p < 0.02).
PLT recovery and CD34 mobilization
Because of reports indicating that poor mobilization
increases the probability for slow and/or poor PLT recov-
ery after PBPCT,22 we performed an analysis comparing
Fig. 2. Time to early (A) and late PLT engraftment (B) in group A and group O patients at 
high (CD34 > 5 [¥106]) and low (CD34 < 3 [¥106]) CD34+ cell doses. Also shown are the 
Kaplan-Meier probabilities for early (B, C) and late PLT engraftment (E, F) by CD34+ cell 
dose in group A (B, E) and group O (C, F) patients, respectively. Engraftment times at 
high (- - -) and low (—) CD34+ transplant doses was compared by the log-rank test.
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the number of PBPC collections per patient relative to late
PLT engraftment at low CD34+ doses. On average, patients
requiring more than 35 days for late PLT engraftment
needed slightly more PBPC collections, with 70 percent of
patients requiring at least six PBPC collections to achieve
a CD34 cell dose of greater than 2 ¥ 106 per kg (5.5 ± 1.9;
range, 3-7). When we examined all patients transplanted
at low CD34+ doses, however, we found no correlation
between the number of PBPC collections and late PLT
engraftment (p > 0.15).
We also examined six of seven patients with poor
mobilization who required “remobilization” with GM–CSF
and G–CSF or high dose G–CSF. Although these patients
required between 8 and 10 leukapheresis procedures per
patient, there was no significant delay in either early
(range, 10-16 days) or late (range, 10-28 days) PLT engraft-
ment. Likewise, there was no correlation between ABO
type and poor mobilization in this group of patients
(group A, n = 2; group B, n = 1; group O, n = 2; group AB,
n = 1). In summary, poor mobilization is not correlated
with either delayed late PLT engraft-
ment or group O phenotype.
DISCUSSION
Advances in PBPC mobilization, col-
lection, and transplant support, par-
ticularly the use of G–CSF and other
growth factors, have markedly
decreased the morbidity and
mortality associated with PBPCT by
decreasing the period of absolute
neutropenia.22,27 As a consequence,
the vast majority of patients achieve
WBC engraftment within 2 weeks of
transplant.20-24 In contrast, many
patients still experience delays in PLT
Fig. 3. Kaplan-Meier probability for early (A) and late (B) PLT engraftment in all group A 
(···), non-group O (– · –), and group O (—) patients at low CD34 transplant doses. There 
was a significant delay in late PLT engraftment in group O patients (p < 0.001, log-rank 
test).
TABLE 4. Group O vs. group A and non-group O patients at low CD34 doses
Group O
(mean ± SD)
Group A Non-group O*
Mean ± SD P value† Mean ± SD P value†
Number of patients 18 28 36
Absolute neutrophil count > 500 (days) 11.9 ± 1.1 11.5 ± 1.0 NS 11.5 ± 0.9 NS
PLT count > 20 ¥ 109/L (days) 16.0 ± 2.6 14.5 ± 4.3 NS 14.6 ± 4.2 NS
PLT count > 50 ¥ 109/L(days)‡ 32.4 ± 13.3 18.5 ± 6.4 <0.001 19.6 ± 7.9 <0.001
Percent engrafting < 20 days§ 13 77 <0.005 73.7 <0.005
Percent engrafting > 40 days§ 50 6 <0.01 4.5 <0.005
Number of units of PLTs 30.8 ± 17.7 28 ± 16.7 NS 27.2 ± 14.0 NS
transfused (range) (5-70) (5-80) (5-80)
Number of units of RBCs 6.7 ± 3.4 5.0 ± 2.4 <0.05 5.2 ± 2.6 NS
transfused (range) (2-12) (2-12) (2-12)
CD34 dose (¥106/kg) 2.41 ± 0.31 2.36 ± 0.35 NS 2.36 ± 0.33 NS
MNCs/kg (¥108/kg) 3.63 ± 3.03 4.02 ± 3.05 NS 3.78 ± 3.38 NS
Number of PBPC procedures/ 4.3 ± 3.1 4.1 ± 2.3 NS 4.0 ± 2.4 NS
patient (range) (1-8) (1-8) (1-10)
Patient age, years  49 ± 14.5 44 ± 15 NS 46 ± 15.3 NS
(range) (22-62) (21-71) (21-71)
Sex (%)
Male 61 70 NS 66 NS
Female 39 30 NS 33 NS
Primary diagnosis (%)
Hodgkin’s lymphoma 33 41 NS 33 NS
Non-Hodgkin’s lymphoma 33 37 NS 42 NS
Multiple myeloma 33 22 NS 22 NS
* All non-group O patients (group A, B and AB).
† T test; NS = not significant (p > 0.05).
‡ Difference between group O, group A, and all non-group O also significant by multivariate analysis (p = 0.0013).
§ Chi-square test.
|| Whole blood–derived PLT concentrates (99.3% of all PLTs). Two patients each received a single unit of apheresis PLT concentrates (0.7% 
total) based on available inventory. Neither patient had evidence of clinical PLT refractoriness.
HOFFMANN ET AL.
892 TRANSFUSION Volume 45, June 2005
engraftment with the attendant risks of bleeding, alloim-
munization, multiorgan failure, and increased mortality.28-30
Although many clinical factors are reportedly associated
with delays in PLT engraftment,28 the single strongest pre-
dictor is the CD34+ cell dose. Several studies have verified
a significant inverse relationship between CD34+ cell dose
and PLT engraftment kinetics, with an estimated thresh-
old minimum of at least 5 ¥ 106 CD34+ cells per kg of body
weight for rapid PLT recovery.20-24 PBPCT at low CD34+
doses, however, does not guarantee slow PLT engraftment,
suggesting the involvement of other factors.28,31
We also found a strong correlation between CD34+
cell dose and the rate of PLT recovery. Although WBC
engraftment was essentially equivalent at all CD34+ doses
of greater than 2 ¥ 106 per kg, there was a significant dose-
response relationship between CD34 dose and early and
late PLT engraftment. As reported,20-22 rapid PLT engraft-
ment was observed at 5 ¥ 106 CD34+ cells per kg with no
significant shortening at higher CD34 doses (data not
shown). Interestingly, we found nearly equivalent mean
engraftment times at intermediate CD34 doses (>3 ¥ 106).
In contrast, autologous PBPCT at CD34 doses <3 ¥ 106
CD34+ cells per kg of body weight were associated with
significant delays in PLT engraftment. Our findings are
consistent with other studies, but suggest that a threshold
yield of 3 ¥ 106 CD34+ cells per kg is sufficient for rapid
WBC and early PLT engraftment.
The relationship between CD34+ PBPC dose and PLT
engraftment kinetics is believed to reflect the dose of
committed megakaryocyte progenitors transplanted.32-35
Mobilized CD34+ PBPCs are a heterogeneous population
consisting of uncommitted pluripotent progenitor cells
and primitive lineage-committed progenitors, including
early megakaryocyte progenitors, which comprise 6 to
8 percent of all CD34+ cells (range, 1%-28%).34-36 Several
clinical investigators have shown that the dose of these
early committed megakaryocyte progenitors, as deter-
mined by CD34+ CD41+ cells, is inversely related to the
rate of PLT engraftment in vivo (r = -0.60 to 0.81).32,33,35
Optimal engraftment is observed at CD34+ CD41+ doses
of greater than 1 ¥ 105 per kg of body weight, which is
roughly equivalent to a total CD34+ PBPC dose of at least
5 ¥ 106 per kg of body weight.21,32 Interestingly, transplants
with highly purified, primitive CD34+ cells, which lack
these early megakaryocyte progenitors, are associated
with profoundly delayed PLT engraftment, decreased
marrow megakaryocytes, and altered megakaryocyto-
poiesis.37
We also examined the effect of recipient ABO type and
engraftment. As noted earlier, an H-active antigen is
strongly and developmentally expressed on progenitor
cells and immature megakaryocytes,13-15 with expression
decreasing with increasing ploidy and megakaryocyte
maturation. As a consequence, we hypothesized that
patient ABO type might influence the rate of PLT recovery
after PBPCT. Contrary to our original hypothesis, there
was a trend toward delayed engraftment at low CD34+ cell
doses in group O patients. This delay was independent of
other potential confounding factors and was specific for
CD34+ doses between 2 ¥ 106 and 3 ¥ 106 per kg of body
weight. To our knowledge, this is the first report suggesting
a relationship between PLT engraftment kinetics and ABO
type.
How ABO group could influence megakaryocyte
development and PLT recovery is unknown. Multiple
studies have shown that the regulation of human mega-
karyocytopoiesis is a complex process that occurs through
a synergistic interaction between megakaryocytic precur-
sors, marrow stromal cells, endothelial cells, and the
ECM.36,38,39 Megakaryocyte adhesion to stromal fibroblasts
and ECM proteins, such as fibronectin, promotes the sur-
vival and expansion of megakaryocytic precursors in vivo
and ex vivo.16-18,40 Interestingly, there is evidence that the
adhesion of megakaryocytes to marrow fibroblasts is
influenced by fucosylation and may, in fact, be fucose-
dependent. Schmitz and colleagues16 were able to inhibit
megakaryocyte adhesion to stromal fibroblasts with fuco-
sylated bovine serum albumin, fucose-specific lectins
(Ulex europeaus lectin-1 and Anguilla anguilla), and sol-
uble H-antigen (aFuc-1,2Galb-HAS).16 Their studies
concluded that megakaryocytes express a fucosylated,
possibly H-active ligand that acts as a counterreceptor for
a fucose-specific lectin on marrow stromal fibroblasts.
Several glycoproteins critical to megakaryocyte devel-
opment and adhesion are known to express ABO-anti-
gens, including GPIIb/IIIa (CD41), GPIba (CD42), and
PECAM (CD31).41,42 An early marker of megakaryocytic
and erythroid differentiation, GPIIb/IIIa binds the ECM
and marrow fibroblasts43 and is required for erythroid,
megakaryocyte, and pleuripotent progenitor mainte-
nance.38 GPIba and PECAM are later megakaryocytic
markers and may contribute to growth arrest and pro-
platelet formation, respectively.38,44,45 ABO antigens are
also expressed by a4b1 and a5b1 integrins, where they are
known to directly influence integrin function. In epithelial
tumors, loss of A/B antigens, with a concomitant increase
in H and LeY, is associated with increased fibronectin
binding, cell adhesion, cell motility, and resistance to apo-
ptosis.46-48 In marrow, integrins mediate CD34+ PBPCs and
megakaryocyte adhesion to ECM and stromal fibro-
blasts,40,45,49 inhibiting apoptosis,50 while promoting
fibroblast growth, megakaryocyte differentiation, and
proplatelet formation.18,39,45
Finally, ABO might influence the binding and cellular
response to required growth factors. The best known
example is the epidermal growth factor receptor, a glyco-
protein important in cell growth regulation and tumori-
genesis.51,52 On RBCs, there is a strong correlation
between ABO type and high-affinity binding.53 In epithe-
lial and PBPCs, ABH influences epidermal growth factor
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and epidermal growth factor receptor expression,54 auto-
phosphorylation, and protein kinase activity.55,56
Although it is not clear whether epidermal growth factor
receptor contributes to megakaryocytic differentiation,57
ABO antigens may be expressed on N-glycans of other
growth factors necessary for fibroblast and megakaryo-
cyte growth.58,59
Based on our findings and those of others, we hypoth-
esize that H is a developmentally regulated antigen that
may play a critical role during megakaryocytopoiesis. Spe-
cifically, fucose-mediated adhesion to marrow fibroblasts
and the ECM, possibly via H/LeY on integrins, may pro-
mote the expansion and/or maintenance of committed,
self-renewing megakaryocytic progenitors while inhibit-
ing terminal differentiation.16,17 In group O individuals,
fucose-mediated adhesion and signaling may be pro-
longed relative to group A and B patients, leading to
delayed megakaryocyte maturation and PLT recovery. This
delay may be relatively subtle and only observed at limit-
ing numbers of megakaryocyte progenitors.
In summary, we have confirmed the inverse correla-
tion between CD34+ cell dose and PLT engraftment kinet-
ics. In addition, we report that ABO type may influence
PLT engraftment at low CD34+ PBPC doses. Specifically,
there is an increased probability of delayed engraftment
among group O patients at CD34+ doses of 2 ¥ 106 to
3 ¥ 106 per kg of body weight. With the advent of ex vivo
culturing techniques, it may now be possible to delineate
the regulation and role of ABO antigen expression in
megakaryocytopoiesis. In contrast, humanized murine
PBPCT models, utilizing SCID mice transplanted with
human PBPCs,60 may not be applicable owing to intrinsic
differences in ABO and glycosyltransferase expression
between mice and humans.61
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